Imugene Issues 35.4 Million New Shares in ASX Placement

Imugene ( (AU:IMU) ) has provided an announcement.

Imugene Limited has issued 35,445,999 fully paid ordinary shares at $0.18 per share under a previously announced placement, expanding its share capital on the ASX. The company confirmed the shares were issued without a prospectus under applicable Corporations Act provisions and stated it remains compliant with its continuous disclosure and financial reporting obligations, indicating a routine capital management step to support its ongoing operations and clinical pipeline.

The notice affirms there is no excluded information that must be disclosed under the Corporations Act, reinforcing regulatory transparency for existing and new shareholders. The placement underscores Imugene’s continued access to equity markets to fund development of its immuno-oncology portfolio, which may influence shareholder dilution while potentially strengthening the company’s financial capacity for advancing its cancer therapies.

The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.18 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is a clinical-stage immuno-oncology company developing novel immunotherapies designed to activate the immune system of cancer patients to treat and eradicate tumours. Its pipeline includes the off-the-shelf allogeneic CAR T cell therapy azer-cel targeting CD19 for blood cancers and the CF33 oncolytic virotherapy platform for a range of solid tumours, often in combination with standard-of-care and emerging immunotherapies.

Average Trading Volume: 1,497,604

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$56.27M

For an in-depth examination of IMU stock, go to TipRanks’ Overview page.